Arena Pharmaceuticals, Inc.
ARNADrugs in Pipeline
5
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Etrasimod
Ulcerative Colitis
Etrasimod 1 mg
Atopic Dermatitis
APD356-lorcaserin hydrochloride
Smoking Cessation
Olorinab
Crohn's Disease
APD125
Insomnia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Etrasimod | Phase 3 | Ulcerative Colitis | - | - |
Etrasimod 1 mg | Phase 2 | Atopic Dermatitis | - | - |
APD356-lorcaserin hydrochloride | Phase 2 | Smoking Cessation | - | - |
Olorinab | Phase 2 | Crohn's Disease | - | - |
APD125 | Phase 2 | Insomnia | - | - |
Frequently asked questions
What is in Arena Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Arena Pharmaceuticals, Inc.'s (ARNA) pipeline across Phase 3, Phase 2. Its lead program is Etrasimod (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Arena Pharmaceuticals, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Arena Pharmaceuticals, Inc. (ARNA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ARNA biotech catalysts?→
Add ARNA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Arena Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.